Overview

Beginning a Randomized Evaluation of the AGE Breaker Alagebrium in Diastolic Heart Failure (BREAK-DHF-I)

Status:
Terminated
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
This study is being done to evaluate the safety and effectiveness of alagebrium in subjects diagnosed with diastolic heart failure. The primary assessment for effectiveness is the assessment of exercise tolerance.
Phase:
Phase 2
Details
Lead Sponsor:
Synvista Therapeutics, Inc